KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)

NCT01626664 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

71

Enrollment

INDUSTRY

Sponsor class

Conditions

Adult T-cell Leukemia-Lymphoma

Interventions

BIOLOGICAL: KW-0761
DRUG: Pralatrexate
DRUG: gemcitabine plus oxaliplatin
DRUG: DHAP

Sponsor

Kyowa Kirin, Inc.